The Food and Drug Administration (FDA) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension ...

Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in one healthcare system formulary led to increased healthcare utilization, a ...

Miguel Divo shows his patient, Joel Rubinstein, a dry powder inhaler. It has a much lower carbon footprint than a traditional inhaler while being equally effective for many patients with asthma. Jesse ...

Most people with asthma and other lung diseases have no idea that commonly prescribed inhalers are helping make the planet warmer. Each puff has about the same climate impact as driving a gas-powered ...

Flovent, a popular corticosteroid inhaler used to treat asthma, is no longer available. The global manufacturer, Glaxo Smith Kline (GSK), announced in May that the medications — Flovent HFA, a metered ...

Switching from a metered dose inhaler to a dry powder version for maintenance therapy more than halves the carbon footprint of people with asthma, and without any worsening of their condition, finds a ...

Please provide your email address to receive an email when new articles are posted on . Almost all of the estimated 1.15 MMT of CO 2 equivalent emissions in 2022 came from metered-dose inhalers. The ...

Dr. Miguel Divo, a lung specialist at Brigham and Women’s Hospital, sits in an exam room, across from one of his patients with asthma. Joel Rubinstein, a retired psychiatrist, is about to get a ...

Switching from a metered-dose inhaler to a dry powder version for maintenance therapy more than halves the carbon footprint of people with asthma, and without any worsening of their condition, finds a ...

The pros and cons to using a dry powder inhaler as treatment for chronic obstructive pulmonary disease. Neil Minkoff, MD: Dr Drummond, we’ve talked a little bit about the differences. You brought some ...

Aptar Pharma pulled the trigger on a deal for Pharmaxis’ Orbital high payload dry powder inhaler technology, paying $2.5 million for a worldwide license with the same again to follow if it chooses to ...

Switching from a metered-dose to a dry-powder inhaler after a formulary change increased emergency department visits and hospitalizations in people with COPD or asthma. The absolute changes in risk ...